AMMOL
MCID: ACT193
MIFTS: 49

Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22) (AMMOL) malady

Categories: Rare diseases, Cancer diseases, Blood diseases, Bone diseases, Immune diseases

Aliases & Classifications for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

Aliases & Descriptions for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22):

Name: Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22) 50 56
Acute Myelomonocytic Leukemia 50 56 29 69
Aml with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22) 50 56
Aml M4 50 56
Ammol 50 56
Aml with Inv(16)(p13.1q22) or T(16;16)(p13.1;q22) 50
Acute Myeloblastic Leukemia Type 4 50
Leukemia, Acute Myelomonocytic 13
Leukemia Myelomonocytic Acute 52
Cbfb-Myh11 50
Aml-M4 50

Characteristics:

Orphanet epidemiological data:

56
acute myelomonocytic leukemia
Inheritance: Not applicable; Age of onset: Adult;

Classifications:



External Ids:

ICD10 via Orphanet 34 C92.5
MESH via Orphanet 43 D015479
UMLS via Orphanet 70 C0023479
ICD10 33 C92.5

Summaries for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

NIH Rare Diseases : 50 acute myelomonocytic leukemia (amml) is a cancer that typically develops in the bone marrow and blood of older individuals.  amml is one type of acute myeloid leukemia, a group of blood cancers that occur when the amount of white blood cells increases rapidly.  symptoms of amml often include fatigue (due to anemia) or easy bruising or bleeding (due to thrombocytopenia).  the cause of amml is currently unknown.  treatment typically consists of chemotherapy. last updated: 2/12/2013

MalaCards based summary : Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22), also known as acute myelomonocytic leukemia, is related to acute leukemia and neurofibromatosis, and has symptoms including fatigue and fever. An important gene associated with Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22) is CBFB (Core-Binding Factor Beta Subunit), and among its related pathways/superpathways are PAK Pathway and Pathways in cancer. The drugs Cyclophosphamide and Busulfan have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and myeloid, and related phenotypes are Increased shRNA abundance (Z-score > 2) and homeostasis/metabolism

Related Diseases for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

Diseases related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22) via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 110)
id Related Disease Score Top Affiliating Genes
1 acute leukemia 29.4 DNTT FLT3 KMT2A MPO
2 neurofibromatosis 29.2 DNTT FLT3 KIT KMT2A MPO
3 acute lymphocytic leukemia 28.3 CREBBP DNTT ETV6 FLT3 KIT KMT2A
4 leukemia, acute myelomonocytic, somatic, somatic 12.1
5 leukemia 10.9
6 acute motor-sensory axonal neuropathy 10.2 FLT3 MPO
7 acute respiratory distress syndrome 10.2 FLT3 KIT
8 paramyloidosis 10.2 CBFB MYH11
9 intracranial sinus thrombosis 10.2 KIT MPO
10 glycogen storage disease type 0 10.2 FLT3 KMT2A
11 acute necrotizing encephalopathy 10.2 KMT2A MPO
12 sarcoma 10.2
13 rnase t2-deficient leukoencephalopathy 10.2 ETV6 KMT2A
14 montefiore syndrome 10.2 ETV6 FLT3
15 eosinophilia-myalgia syndrome 10.1 CSF1R KIT
16 vulvovaginal gingival syndrome 10.1 ETV6 MPO
17 agammaglobulinemia 8, autosomal dominant 10.1 ETV6 FLT3 KIT
18 hyperandrogenism due to cortisone reductase deficiency 10.1 FLT3 KIT
19 comt-related pain sensitivity alteration 10.1 ETV6 RUNX1
20 thompson baraitser syndrome 10.1 DNTT RUNX1
21 unilateral hemispheric polymicrogyria 10.1 FLT3 KIT RUNX1
22 dupuytren contracture 10.1 FLT3 KIT RUNX1
23 necrotic uveal melanoma 10.0 CREBBP FLT3
24 multiple myeloma 10.0
25 lymphoma, small cleaved-cell, diffuse 10.0 DNTT KMT2A MPO
26 colorectal adenoma 10.0 ETV6 FLT3 RUNX1
27 acute myocardial infarction 10.0 ETV6 FLT3 RUNX1
28 lymphomatoid granulomatosis 10.0 ETV6 KMT2A RUNX1
29 myelodysplastic syndrome 10.0
30 lymphoma 10.0
31 mixed astrocytoma-ependymoma-oligodendroglioma 10.0 ETV6 KMT2A RUNX1
32 cutis laxa 10.0 CSF1 CSF1R
33 diffuse glomerulonephritis 9.9 ETV6 KIT
34 gingivitis 9.9
35 mycosis fungoides 9.9
36 amblyopia 9.9 ETV6 FLT3 RUNX1
37 malignant giant cell tumor 9.9 CSF1 CSF1R
38 diplegia of upper limb 9.9 CSF1 CSF1R
39 adult respiratory distress syndrome 9.9 CREBBP FLT3 KMT2A MPO
40 liver disease 9.9 ETV6 FLT3 KIT RUNX1
41 chronic lymphocytic leukemia 9.8
42 macroglobulinemia 9.8
43 chronic myelomonocytic leukemia 9.8
44 vasculitis 9.8
45 myeloid sarcoma 9.8
46 myeloid leukemia 9.8
47 familial hyperaldosteronism 9.8 CBFB CSF1R FLT3 KIT RUNX1
48 actinobacillosis 9.7 ETV6 FLT3 KIT MPO RUNX1
49 malignant testicular leydig cell tumor 9.7 DNTT FLT3 MPO MYH11 RUNX1
50 bleeding disorder, platelet-type, 18 9.7 DNTT FLT3 KMT2A MPO RUNX1

Graphical network of the top 20 diseases related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22):



Diseases related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22)

Symptoms & Phenotypes for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

UMLS symptoms related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22):


fatigue, fever

GenomeRNAi Phenotypes related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22) according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.06 MPO
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.06 FLT3 KIT DNTT
3 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.06 FLT3
4 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.06 FLT3
5 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.06 FLT3
6 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.06 FLT3
7 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.06 DNTT FLT3
8 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.06 MPO
9 Increased shRNA abundance (Z-score > 2) GR00366-A-138 10.06 DNTT
10 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.06 DNTT
11 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.06 KIT
12 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.06 KIT MPO DNTT
13 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.06 DNTT
14 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.06 FLT3
15 Increased shRNA abundance (Z-score > 2) GR00366-A-170 10.06 KIT
16 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.06 MPO
17 Increased shRNA abundance (Z-score > 2) GR00366-A-182 10.06 DNTT
18 Increased shRNA abundance (Z-score > 2) GR00366-A-186 10.06 MPO
19 Increased shRNA abundance (Z-score > 2) GR00366-A-197 10.06 DNTT
20 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.06 FLT3
21 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.06 MPO
22 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.06 KIT
23 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.06 MPO
24 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.06 KIT
25 Increased shRNA abundance (Z-score > 2) GR00366-A-57 10.06 MPO
26 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.06 MPO
27 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.06 MPO FLT3
28 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.06 DNTT
29 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.06 KIT
30 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10.06 KIT
31 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.06 KIT

MGI Mouse Phenotypes related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22):

44 (show all 19)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.29 CBFB CREBBP CSF1 CSF1R DNTT ETV6
2 cardiovascular system MP:0005385 10.28 CBFB CREBBP CSF1 DNTT ETV6 KIT
3 cellular MP:0005384 10.27 CBFB CREBBP CSF1 CSF1R ETV6 FLT3
4 hematopoietic system MP:0005397 10.26 ETV6 FLT3 KIT KMT2A MPO RUNX1
5 growth/size/body region MP:0005378 10.24 CBFB CREBBP CSF1 CSF1R ETV6 FLT3
6 immune system MP:0005387 10.24 CBFB CREBBP CSF1 CSF1R DNTT ETV6
7 endocrine/exocrine gland MP:0005379 10.15 FLT3 KIT RUNX1 CBFB CREBBP CSF1
8 mortality/aging MP:0010768 10.14 CBFB CREBBP CSF1 CSF1R ETV6 FLT3
9 integument MP:0010771 10.13 CREBBP CSF1 CSF1R ETV6 KIT KMT2A
10 craniofacial MP:0005382 10.04 CBFB CREBBP CSF1 CSF1R KIT KMT2A
11 embryo MP:0005380 10.03 CBFB CREBBP ETV6 KIT KMT2A RUNX1
12 limbs/digits/tail MP:0005371 9.93 CREBBP CSF1 CSF1R KIT KMT2A CBFB
13 liver/biliary system MP:0005370 9.91 CBFB CREBBP CSF1 KIT KMT2A RUNX1
14 neoplasm MP:0002006 9.87 RUNX1 CBFB CREBBP ETV6 FLT3 KIT
15 no phenotypic analysis MP:0003012 9.86 ETV6 FLT3 KIT KMT2A RUNX1 CBFB
16 muscle MP:0005369 9.85 MYH11 CREBBP CSF1 KIT KMT2A MPO
17 normal MP:0002873 9.76 RUNX1 CBFB CREBBP CSF1R DNTT ETV6
18 respiratory system MP:0005388 9.43 CBFB CREBBP CSF1 KIT MYH11 RUNX1
19 skeleton MP:0005390 9.23 CBFB CREBBP CSF1 CSF1R FLT3 KIT

Drugs & Therapeutics for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

Drugs for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22) (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 416)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
2
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 55-98-1 2478
3
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1 135968-09-1
4
Thiotepa Approved Phase 4,Phase 3,Phase 2,Phase 1 52-24-4 5453
5 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1
6 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
7 Antilymphocyte Serum Phase 4,Phase 2,Phase 3,Phase 1
8 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
9 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1
10
Tacrolimus Approved, Investigational Phase 3,Phase 2,Phase 1 104987-11-3 445643 439492
11
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1 65271-80-9 4212
12
Daunorubicin Approved Phase 3,Phase 2,Phase 1 20830-81-3 30323
13
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
14
Idarubicin Approved Phase 3,Phase 2,Phase 1,Early Phase 1 58957-92-9 42890
15
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 147-94-4 6253
16
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
17
Amsacrine Approved Phase 3 51264-14-3 2179
18
Melphalan Approved Phase 2, Phase 3, Phase 1 148-82-3 4053 460612
19
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 498142 38904
20
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1 24280-93-1 446541
21
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2,Phase 1 128794-94-5 5281078
22
Fludarabine Approved Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
23
rituximab Approved Phase 3,Phase 2,Phase 1 174722-31-7 10201696
24
Prednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 1 50-24-8 5755
25
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
26
Mesna Approved Phase 3,Phase 1,Phase 2 3375-50-6 598
27
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
28
Ofloxacin Approved Phase 3 82419-36-1 4583
29
Clofarabine Approved, Investigational Phase 2, Phase 3, Phase 1 123318-82-1 119182
30
Cefepime Approved Phase 3,Phase 1 88040-23-7 5479537
31
Thioguanine Approved Phase 3,Phase 1 154-42-7 2723601
32
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 1 83-43-2 6741
33
Azacitidine Approved, Investigational Phase 2, Phase 3, Phase 1 320-67-2 9444
34
Decitabine Approved, Investigational Phase 3,Phase 2,Phase 1 2353-33-5 451668
35
Aldesleukin Approved Phase 3,Phase 1,Phase 2 85898-30-2, 110942-02-4
36
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
37
Carmustine Approved Phase 3,Phase 2 154-93-8 2578
38
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
39
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 1 50-02-2 5743
40
Cyclosporine Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
41
Morphine Approved, Investigational Phase 3 57-27-2 5288826
42
Hydroxyurea Approved Phase 3,Phase 2 127-07-1 3657
43
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
44
Histamine Approved, Investigational Phase 3,Phase 2,Phase 1 75614-87-8, 51-45-6 774
45
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754 657311
46
Cyproheptadine Approved Phase 3,Phase 2 129-03-3 2913
47
Ephedrine Approved Phase 3 299-42-3 9294
48
Ondansetron Approved Phase 3,Phase 2,Phase 1 99614-02-5 4595
49
alemtuzumab Approved, Investigational Phase 2, Phase 3,Phase 1 216503-57-0
50
Pseudoephedrine Approved Phase 3 90-82-4 7028

Interventional clinical trials:

(show top 50) (show all 568)
id Name Status NCT ID Phase
1 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4
2 Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT) Not yet recruiting NCT01339988 Phase 4
3 Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia Unknown status NCT00006045 Phase 3
4 Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00002549 Phase 3
5 Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00004128 Phase 3
6 Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00002658 Phase 3
7 Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission Unknown status NCT00454168 Phase 3
8 Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Unknown status NCT00091234 Phase 2, Phase 3
9 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia Unknown status NCT00002926 Phase 3
10 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3
11 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3
12 Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00006363 Phase 3
13 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Completed NCT00002798 Phase 3
14 Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00372593 Phase 3
15 Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00369317 Phase 3
16 Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00003190 Phase 3
17 Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia Completed NCT00005863 Phase 3
18 Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome Completed NCT00003593 Phase 3
19 Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00005823 Phase 3
20 flt3L in Treating Patients With Acute Myeloid Leukemia Completed NCT00006223 Phase 3
21 Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia Completed NCT00112554 Phase 3
22 Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia Completed NCT00046930 Phase 3
23 Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00121303 Phase 3
24 Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00002517 Phase 3
25 Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Completed NCT00454480 Phase 2, Phase 3
26 Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00002719 Phase 3
27 High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00002945 Phase 3
28 S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML Completed NCT00085709 Phase 3
29 Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00052299 Phase 3
30 S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid Leukemia Completed NCT00005866 Phase 3
31 Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT00152139 Phase 3
32 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
33 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed NCT01305200 Phase 3
34 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
35 Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT00186823 Phase 3
36 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
37 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
38 Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer Completed NCT00265837 Phase 3
39 A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families Completed NCT00782145 Phase 3
40 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3
41 Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma Completed NCT00003187 Phase 2, Phase 3
42 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3
43 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
44 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3
45 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3
46 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3
47 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
48 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3
49 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3
50 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Completed NCT00755040 Phase 3

Search NIH Clinical Center for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22)

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

Genetic tests related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22):

id Genetic test Affiliating Genes
1 Acute Myelomonocytic Leukemia 29

Anatomical Context for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

MalaCards organs/tissues related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22):

39
Bone, Bone Marrow, Myeloid

Publications for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

Variations for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

Expression for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

Search GEO for disease gene expression data for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22).

Pathways for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

GO Terms for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

Cellular components related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22) according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 CSF1-CSF1R complex GO:1990682 8.62 CSF1 CSF1R

Biological processes related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22) according to GeneCards Suite gene sharing:

(show all 21)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.96 CBFB CREBBP ETV6 KMT2A RUNX1
2 transcription from RNA polymerase II promoter GO:0006366 9.9 CBFB ETV6 KMT2A RUNX1
3 positive regulation of cell proliferation GO:0008284 9.84 CSF1 CSF1R FLT3 KIT
4 positive regulation of cell migration GO:0030335 9.72 CSF1 CSF1R KIT
5 protein autophosphorylation GO:0046777 9.7 CSF1R FLT3 KIT
6 peptidyl-tyrosine phosphorylation GO:0018108 9.69 CSF1R FLT3 KIT
7 cytokine-mediated signaling pathway GO:0019221 9.65 CSF1R FLT3 KIT
8 positive regulation of tyrosine phosphorylation of Stat3 protein GO:0042517 9.59 CSF1R KIT
9 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.58 FLT3 KIT
10 homeostasis of number of cells within a tissue GO:0048873 9.58 CSF1 KMT2A
11 cellular response to cytokine stimulus GO:0071345 9.57 CSF1R FLT3
12 osteoclast differentiation GO:0030316 9.49 CSF1 CSF1R
13 macrophage differentiation GO:0030225 9.46 CSF1 CSF1R
14 definitive hemopoiesis GO:0060216 9.43 CBFB KMT2A
15 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.43 CSF1R FLT3 KIT
16 embryonic hemopoiesis GO:0035162 9.4 KIT KMT2A
17 hematopoietic stem cell proliferation GO:0071425 9.37 ETV6 RUNX1
18 myeloid progenitor cell differentiation GO:0002318 9.32 FLT3 KIT
19 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.26 CSF1 CSF1R FLT3 KIT
20 macrophage colony-stimulating factor signaling pathway GO:0038145 9.16 CSF1 CSF1R
21 hemopoiesis GO:0030097 9.02 CSF1 CSF1R FLT3 KIT RUNX1

Molecular functions related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22) according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transferase activity GO:0016740 9.85 CREBBP CSF1R DNTT FLT3 KIT KMT2A
2 transcription factor activity, sequence-specific DNA binding GO:0003700 9.72 CBFB CREBBP ETV6 KMT2A RUNX1
3 protein tyrosine kinase activity GO:0004713 9.43 CSF1R FLT3 KIT
4 protein homodimerization activity GO:0042803 9.35 CSF1 CSF1R FLT3 KIT KMT2A
5 cytokine binding GO:0019955 9.16 CSF1R KIT
6 transmembrane receptor protein tyrosine kinase activity GO:0004714 8.8 CSF1R FLT3 KIT

Sources for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....